GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...

A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its ...

Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval ...

Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark ...

A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the ...

Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a ...

City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...

As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new ...

Pfizer's former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company's ...

As Merck builds out its immunology research lab in London, it's partnering with a local biotech startup that has remained ...

Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s shares $SRRK skyrocketed over ...